Advancing Treatment in Non-Small Cell Lung Cancer: The Role of Immunotherapy and Pembrolizumab-Chemotherapy Combinations
Non-small cell lung cancer, pembrolizumab, immunotherapy, chemotherapy, immune checkpoint inhibitors, and combination therapy
Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality globally. Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs) like pembrolizumab, have transformed NSCLC treatment, improving survival in patients with advanced disease. However, many patients eventually develop resistance or experience progression on immunotherapy. This review focuses on the evolving role of pembrolizumab-chemotherapy combinations, exploring their mechanisms, efficacy, safety profiles, and the potential to overcome immunotherapy resistance. Emerging clinical trials show promising results, suggesting that combining pembrolizumab with chemotherapy can extend survival in patients who have progressed on prior therapies
"Advancing Treatment in Non-Small Cell Lung Cancer: The Role of Immunotherapy and Pembrolizumab-Chemotherapy Combinations", IJNRD - INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (www.IJNRD.org), ISSN:2456-4184, Vol.9, Issue 10, page no.a836-a839, October-2024, Available :https://ijnrd.org/papers/IJNRD2410089.pdf
Volume 9
Issue 10,
October-2024
Pages : a836-a839
Paper Reg. ID: IJNRD_301145
Published Paper Id: IJNRD2410089
Downloads: 00060
Research Area: Humanities All
Country: Pune, Maharashtra, India
ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave
